Spring Quiz 5

Question 1

Darbepoetin Alfa (Brand, Class, MOA)

Answer 1

Aranesp. Hematopoietic, Erythropoietic, Colony Stimulating Factor. Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes.

Question 2

Darbepoetin Alfa (Indication, BBW, Preg)

Answer 2

Anemia. Cardiovascular events, CKD, Cancer, Perisurgery (due to DVT). No.

Question 3

Epoetin Alfa (Brand, Class, MOA)

Answer 3

Procrit, Epogen. Hematopoietic, Erythropoietic, Colony Stimulating Factor. Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes.

Question 4

Epoetin Alfa (Indication, BBW, Preg)

Answer 4

Anemia. Cardiovascular events, CKD, Cancer, Perisurgery (due to DVT). No.

Question 5

Tacrolimus (Brand, Class, MOA)

Answer 5

Prograf. Calcineurin Inhibitor, Immune Suppressant. Suppresses cellular immunity (inhibits T-lymphocyte activation), by binding to an intracellular protein, FKBP-12 and complexes with calcineurin dependent proteins to inhibit calcineurin phosphatase activity.

Question 6

Tacrolimus (Indication, BBW, Preg)

Answer 6

Ppx of organ rejection in heart, kidney, or liver transplant patients. Only experienced physicians should prescribe, serious infections and malignancies. No.

Question 7

Mycophenolate (Brand, Class, MOA)

Answer 7

CellCept. Immunosuppressant Agent. MPA exhibits a cytostatic effect on T and B lymphocytes. It is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which inhibitsde novoguanosine nucleotide synthesis.

Question 8

Mycophenolate (Indication, BBW, Preg)

Answer 8

Ppx of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal, cardiac, or hepatic transplants. Only experienced physicians should prescribe, serious infections and malignancies, and embryo-fetal toxicity. No.

Question 9

Cyclosporine (Brand, Class, MOA)

Answer 9

Neoral, Sandimmune. Calcineurin Inhibitor, Immune Suppressant. Inhibition of production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.

Question 10

Cyclosporine (Indication, BBW, Preg)

Answer 10

Ppx of organ rejection in heart, kidney, or liver transplant patients. Only experienced physicians should prescribe, immunosuppression. No.

Question 11

Sirolimus (Brand, Class, MOA)

Answer 11

Rapamune. Immunosuppressant Agent, mTOR Kinase Inhibitor. Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which inhibits the regulatory kinase, mTOR (mechanistic target of rapamycin). This inhibition suppresses cytokine mediated T-cell proliferation, halting progression from the G1 to the S phase of the cell cycle. It inhibits acute rejection of allografts and prolongs graft survival.

Question 12

Sirolimus (Indication, BBW, Preg)

Answer 12

Tx of lymphangioleiomyomatosis, Ppx of organ rejection in pts receiving renal transplants. Only experienced physicians should prescribe, immunosuppression. No.

Question 13

Everolimus (Brand, Class, MOA)

Answer 13

Afinitor, Zortress. Immunosuppressant Agent, mTOR Kinase Inhibitor, antineoplastic agent. Serves as a mechanistic target of rapamycin (mTOR) inhibitor which has antiproliferative and antiangiogenic properties, and also reduces lipoma volume in patients with angiomyolipoma. Reduces protein synthesis and cell proliferation by binding to the FK binding protein-12 (FKBP-12), an intracellular protein, to form a complex that inhibits activation of mTOR (mechanistic target of rapamycin) serine-threonine kinase activity.

Question 14

Everolimus (Indication, BBW, Preg)

Answer 14

Afinitor only: breast cancer/pancreatic neuroendocrine tumors/renal angiomyolipoma w/ tuberous sclerosis complex, renal cell carcinoma, subependymal giant cell astrocytoma. Zortress only: liver/renal transplantation.Immunosuppression, graft thrombosis, nephrotoxicity, and mortality in heart transplant (all Zortress). No.

Question 15

Antithymocyte globulin (Brand, Class, MOA)

Answer 15

Thyroglobulin. Immunosuppressant Agent, Immune globulin, Polyclonal Antibody. Polyclonal antibody which appears to cause immunosuppression by acting on T-cell surface antigens and depleting CD4 lymphocytes.

Question 16

Antithymocyte globulin (Indication, BBW, Preg)

Answer 16

Tx of acute rejection of renal transplant, used in conjunction with concomitant immunosuppression. Experienced physician. No.

Question 17

Basiliximab Brand, Class, MOA)

Answer 17

Simulect. Immunosuppressant Agent, Monoclonal Antibody. Chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this receptor is expressed on activated T lymphocytes and is a critical pathway for activating cell-mediated allograft rejection.

Question 18

Basiliximab (Indication, BBW, Preg)

Answer 18

Ppx of acute organ rejection in renal transplantation in combination with cyclosporine (modified) and steroids. Experienced physician. No.

Question 19

Alemtuzumab (Brand, Class, MOA)

Answer 19

Campath. Anti-CD52 Antineoplastic Agent, Monoclonal Antibody. Binds to CD52, a nonmodulating antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. After binding to CD52+cells, an antibody-dependent lysis of malignant cells occurs.

Question 20

Alemtuzumab (Indication, BBW, Preg)

Answer 20

Tx of B-cell chronic lymphocytic leukemia(B-CLL). Bone marrow suppression, infusion reactions, infections. No.